Search

Respimat re-usable wins Pharmapack Eco-Design Award

The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.

Cooperation with Google Quantum AI

AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance

AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance

Boehringer and ZEISS partnership eye diseases

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Aservo EquiHaler wins Red Dot 2020 for design quality

Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality

sustainably fighting rabies info hub

Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.

expanded-collaboration-MD-Anderson

The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer

Animal Health partnering interests

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

Boehringer Ingelheim and Fraunhofer partnership

Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products

GastroGard the first imported equine drug in China

GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.

Winners of 2020 BVDzero Case Awards

Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.

The Core of our Leitbild

Who we are and what we strive for

Partnership to Develop Urea Cycle Disorders Therapy

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

LastMile increases access to veterinary care in Africa

Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine

Boehringer Ingelheim half-year results 2023

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Option to Acquire Trutino Biosciences

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.

Nerandomilast (BI 1015550)

Nerandomilast (BI 1015550): PDE4B inhibitor

Koropi

For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.

inauguration_biopharmaceutical_production_facility_vienna

The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.

Phase 1 start of treatment for Geographic Atrophy patients

Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers